Laird Norton Wetherby Wealth Management LLC Sells 2,533 Shares of Boston Scientific Co. (NYSE:BSX)

Laird Norton Wetherby Wealth Management LLC lessened its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 9.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,574 shares of the medical equipment provider's stock after selling 2,533 shares during the period. Laird Norton Wetherby Wealth Management LLC's holdings in Boston Scientific were worth $2,284,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. TFC Financial Management Inc. grew its holdings in shares of Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 210 shares in the last quarter. Colonial Trust Co SC grew its stake in Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 260 shares in the last quarter. West Oak Capital LLC purchased a new stake in shares of Boston Scientific in the fourth quarter worth approximately $29,000. Valley National Advisers Inc. grew its position in Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 286 shares in the last quarter. Finally, Fairway Wealth LLC acquired a new position in Boston Scientific in the 4th quarter valued at approximately $36,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. UBS Group upped their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Robert W. Baird raised their price target on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Royal Bank of Canada raised their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Finally, BTIG Research reiterated a "buy" rating and issued a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, April 23rd. Twenty-three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and a consensus price target of $114.74.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded up $1.14 during trading on Friday, hitting $106.00. 7,288,742 shares of the company's stock traded hands, compared to its average volume of 6,362,216. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The company has a market cap of $156.83 billion, a PE ratio of 84.80, a PEG ratio of 2.79 and a beta of 0.68. The firm's fifty day moving average price is $98.98 and its 200 day moving average price is $96.42.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter last year, the company earned $0.56 EPS. Boston Scientific's revenue was up 20.9% on a year-over-year basis. Analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other news, EVP Jeffrey B. Mirviss sold 4,675 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. This represents a 14.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Bradley Sorenson sold 4,572 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the sale, the executive vice president now directly owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 265,820 shares of company stock valued at $27,406,958. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.